Example: Heart Attack

Search clinical trials for: Miglustat

Total 28 results

NCT03822013

Recruiting

Effects of Miglustat Therapy on Infantile Type of Sandhoff and Taysachs Diseases (EMTISTD)

Conditions: GM2 Gangliosidosis; Supportive Care
NCT01760564

Completed

Application of Miglustat in Patients With Niemann-Pick Type C

Conditions: Niemann-Pick Disease Type C
NCT04768166

Not yet recruiting

Testing Miglustat Administration in Subjects With Spastic Paraplegia 11

Conditions: Hereditary Spastic Paraparesis
NCT02520934

Active, not recruiting

Miglustat on Gaucher Disease Type IIIB

Conditions: Gaucher Disease
NCT00319046

Completed

Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease

Conditions: Gaucher Disease Type 1
NCT03910621

Recruiting

Safety and Efficacy of Miglustat in Chinese NPC Patients

Conditions: Niemann-Pick Disease, Type C
NCT00517153

Completed

Miglustat in Niemann-Pick Type C Disease

Conditions: Niemann-Pick Type C Disease
NCT02185651

Terminated

A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated Reaction

Conditions: Pompe Disease; Hypersensitivity Reaction
NCT02325362

Completed

Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation

Conditions: Cystic Fibrosis
NCT00945347

Completed

Does a Nasal Instillation of Miglustat Normalize the Nasal Potential Difference in Cystic Fibrosis Patients ?

Conditions: Cystic Fibrosis
NCT00418847

Completed

Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis

Conditions: Gangliosidoses GM2
NCT00537602

Terminated

Miglustat / OGT 918 in the Treatment of Cystic Fibrosis

Conditions: Cystic Fibrosis
NCT00742092

Completed

Miglustat in Cystic Fibrosis

Conditions: Cystic Fibrosis
NCT02030015

Recruiting

Synergistic Enteral Regimen for Treatment of the Gangliosidoses

Conditions: GM1 Gangliosidoses; GM2 Gangliosidoses; Tay-Sachs Disease; Sandhoff Disease
NCT00672022

Completed

Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses

Conditions: GM2 Gangliosidoses; Tay-Sachs; Sandhoff Disease
NCT00194649

Completed

Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)

Conditions: Contraception
NCT01822028

Completed

Two Period / Two Treatment Cross-over to Assess the Effect of Florastor® on Gastrointestinal Tolerability, Safety, and PK in Healthy Subjects Receiving Zavesca®

Conditions: Diarrhea
NCT04138277

Recruiting

A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD

Conditions: Pompe Disease (Late-onset)
NCT00041535

Completed

OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease

Conditions: Gaucher Disease
NCT03911505

Recruiting

ZIP Study - A Study to Evaluate the PK, Safety, Efficacy, and PD With ATB200/AT2221 in LOPD Subjects Aged 12 to <18

Conditions: Pompe Disease (Late-onset)
NCT00000692

Completed

Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex

Conditions: HIV Infections
NCT03729362

Completed

PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD

Conditions: Pompe Disease (Late-onset)
NCT01451879

Completed

Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies

Conditions: Pompe Disease
NCT02675465

Active, not recruiting

First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

Conditions: Pompe Disease
NCT00316498

Completed

Saccadic Eye Movements in Patients With Niemann-Pick Type C Disease

Conditions: Niemann Pick Diseases